5 results
The primary objective of the study is to assess the effect of missed doses of atomoxetine and OROS methylphenidate in ADHD patients who are stable on pharmacotherapy based on the patient*s daily behavior as assessed by the Daily Parent Report of…
1) The BioNIR is non-inferior to the Resolute for the primary clinical endpoint of target lesion failure (TLF) (defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR) at 12 months2/ The BioNIR is non-inferior to…
The BioNIR is non-inferior to the Resolute for the primary angiographic of in-stent late loss at 6 months
Primary objectives: The first primary objective is to study the expression of PD-L1 in normal tissue and lymphoma lesions before CAR T-cell therapy in LBCL patients by 89Zr-atezolizumab PET/CT imaging and to correlate the pretreatment 89Zr-…
Primary objective: To evaluate the comparative long-term safety of TAK-503 treatment (formerly known as SPD503) in children and adolescentsaged 6 to 17 years diagnosed with ADHD for whom stimulants are not suitable, not tolerated, or shown to…